Jacobson Pharma Management
Management Kriterienprüfungen 1/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Derek Sum
Geschäftsführender
HK$20.8m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 19.6% |
| Amtszeit als Geschäftsführer | 8.7yrs |
| Eigentum des Geschäftsführers | 60.2% |
| Durchschnittliche Amtszeit des Managements | keine Daten |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 8.5yrs |
Jüngste Management Updates
Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21
Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Recent updates
Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues
Dec 21Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025
Nov 27These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Nov 28Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268
Sep 25Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 28Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Jul 14Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012
Nov 29Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015
Sep 24Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year
Sep 16Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares
Feb 03
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)
Jan 24Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?
Dec 27Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?
Dec 12Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years
Dec 03Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2024 | HK$21m | HK$4m | HK$186m |
| Dec 31 2023 | n/a | n/a | HK$221m |
| Sep 30 2023 | n/a | n/a | HK$217m |
| Jun 30 2023 | n/a | n/a | HK$234m |
| Mar 31 2023 | HK$14m | HK$3m | HK$175m |
| Dec 31 2022 | n/a | n/a | HK$207m |
| Sep 30 2022 | n/a | n/a | HK$203m |
| Jun 30 2022 | n/a | n/a | HK$190m |
| Mar 31 2022 | HK$5m | HK$3m | HK$178m |
| Dec 31 2021 | n/a | n/a | HK$166m |
| Sep 30 2021 | n/a | n/a | HK$154m |
| Jun 30 2021 | n/a | n/a | HK$164m |
| Mar 31 2021 | HK$5m | HK$4m | HK$174m |
| Dec 31 2020 | n/a | n/a | HK$183m |
| Sep 30 2020 | n/a | n/a | HK$191m |
| Jun 30 2020 | n/a | n/a | HK$203m |
| Mar 31 2020 | HK$5m | HK$4m | HK$214m |
| Sep 30 2019 | n/a | n/a | HK$273m |
| Jun 30 2019 | n/a | n/a | HK$259m |
| Mar 31 2019 | HK$5m | HK$4m | HK$245m |
| Dec 31 2018 | n/a | n/a | HK$235m |
| Sep 30 2018 | n/a | n/a | HK$219m |
| Jun 30 2018 | n/a | n/a | HK$211m |
| Mar 31 2018 | HK$6m | HK$4m | HK$202m |
Vergütung im Vergleich zum Markt: DerekDie Gesamtvergütung ($USD1.75M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Hong Kong ($USD349.42K).
Entschädigung vs. Einkommen: DerekDie Bezüge der Mitarbeiter sind im vergangenen Jahr um mehr als 20 % gestiegen.
Geschäftsführer
Derek Sum (61 yo)
8.7yrs
Amtszeit
HK$20,779,000
Vergütung
Mr. Kwong Yip Sum, also known as Derek, is Non-Executive Chairman of the Board at JBM (Healthcare) Limited since September 22, 2020. He joined the company and its subsidiaries September 22, 2020. With exte...
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Chairman | 8.7yrs | HK$20.78m | 60.18% HK$ 738.8m | |
| VP of Administration & Executive Director | 7.7yrs | HK$3.18m | 0.42% HK$ 5.2m | |
| Executive Director | 8.5yrs | HK$6.77m | 2.04% HK$ 25.1m | |
| Independent Non-Executive Director | 8.5yrs | HK$230.00k | keine Daten | |
| Independent Non-Executive Director | 8.2yrs | HK$230.00k | keine Daten | |
| Member of Scientific Advisory Committee | 8.5yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Committee | 8.5yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Committee | 8.5yrs | keine Daten | keine Daten | |
| Non-Executive Director & Member of Scientific Advisory Committee | 8.5yrs | HK$230.00k | keine Daten | |
| Independent Non-Executive Director | 8.2yrs | HK$230.00k | 0.030% HK$ 372.0k |
8.5yrs
Durchschnittliche Betriebszugehörigkeit
61yo
Durchschnittliches Alter
Erfahrener Vorstand: 2633Die Vorstandsmitglieder gelten als erfahren (8.1 Jahre durchschnittliche Amtszeit).